Carvykti (cilta-cabtagene autoleucel)

cilta-cabtagene autoleucel · Janssen Biotech, Inc. and Legend Biotech

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Carvykti (cilta-cabtagene autoleucel), covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy [Phase 3]

See pricing